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Parkinson’s disease (PD) extends beyond movement to often encompass a range of psychiatric 
phenomena, such that it has been viewed as the prototypical neuropsychiatric disorder (1). While 
the movement disorder is primarily linked to a central dopamine deficit, neurodegenerative events 
in the main noradrenergic, serotoninergic, and cholinergic nuclei precede motor symptom onset, 
by a decade or longer (2, 3). Thus, the high prevalence of neuropsychiatric symptoms could be seen 
as the inexorable consequence of a multifaceted neuropathology, and some of these are, in fact, 
recommended by the EFNS/MDS-ES Task force as criteria to aid differential diagnosis (4).
Subtle tensions regarding the ontology of psychiatric phenomena in PD are nonetheless apparent 
in that they are variously referred to as symptoms, linking them directly to the disease, complications 
arising from treatments that target dopamine to alleviate motor symptoms, or more generally as 
dysfunction or impairment. This reluctant consensus most likely mirrors the evolving state of the 
science on the complex problem of resolving symptoms from complications in PD, which poses a 
number of challenges. Disabling motor impairment rules out the possibility of withdrawing medica-
tion in order to reveal the psychiatric sequelae of the disease unconfounded by it. Moreover, these 
behaviors may not be seen in newly diagnosed, drug naive patients due to their time course and 
the inherent heterogeneity of the disease. However, resolving the nosological status of psychiatric 
symptoms in a movement disorder, which fall between the remits of neurology and psychiatry, in an 
evidence-based manner and systematically integrating them into the framework of a disease of the 
brain with both motor and psychiatric manifestations arising from pervasive degenerative change 
is important. Delineating symptoms and differentiating them from complications in PD has clear 
implications for patients’ perceptions of their illness, their attributions, choices, and communication 
with clinicians, and, ultimately, effective clinical management.
Early psychiatric changes in people who go on to develop motor symptoms consistent with PD 
represent compelling candidates for the category of neuropsychiatric symptoms that stem from the 
disease itself.
Anxiety disorders (5, 6) and depression (7) may precede the onset of motor symptoms by one 
or even two decades and significantly increase the risk of a future PD diagnosis. In addition, some 
patients who experience on–off fluctuations in motor function also experience profound fluctuation 
in mood, which can rapidly change from depressed and suicidal to euphoric or even hypomanic (8). 
Mood swings are not reliably linked to dopaminergic dosing or motor symptom deterioration (9, 10), 
but are rather seen more often in patients with a pre-existing psychiatric history or concurrent use of 
psychiatric medication (11), suggesting these may in fact be part of a larger symptom constellation. 
Thus, while the general population prevalence of depression suggests that at least in some people 
with PD this will be comorbid and psychological and psychosocial factors may also be at play, con-
vergent evidence indicates that for many others this will be accurately, and usefully, conceptualized 
as a symptom of PD. For some patients, mood disturbance predates motor symptoms and coincides 
chronologically with the degenerative changes in the locus coeruleus and raphe nuclei seen in the 
earliest Braak stages leading to early compromise on monoaminergic processes. Depression is the 
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second highest quality-of-life predictor in PD (12), and, notably, 
patients who invoke PD as a major cause for their symptoms 
attribute these to perceived psychosocial effects related to their 
illness rather than its neurobiology (13). Such attributions and 
an emphasis on motor symptoms in patient reports and clinician 
investigations which often overlook non-motor symptoms (14) 
may contribute to their underdiagnosis and undertreatment (15).
REM sleep behavior disorder (RBD) is another prodromal 
symptom of PD indicative of a synucleinopathy, where noradr-
energic deficits in particular, arising due to the degeneration of 
the locus coeruleus, appear to play an important role (16).
Conversely, symptoms also emerge in the course of the 
heterogeneous progression of PD. While dementia appears 
in some patients at the end of a long disease course, in others, 
this profound cognitive decline occurs relatively early on. The 
early features of cognitive decline leading to dementia, namely, 
early visuospatial and memory deficits associated with posterior 
cortical compromise and evidence of cholinergic dysfunction 
(17), appear to be distinct from the more prevalent pattern of 
mild cognitive impairment in the form of executive deficits that 
mirror monoaminergic dysfunction (18). Thus, profound cho-
linergic deficits, amyloid and synuclein aggregates contribute to 
dementia [for review, see Ref. (19)] and demarcate it as a distinct 
neuropsychiatric symptom within the heterogeneity of cognitive 
impairment seen in PD.
Other psychiatric changes remain less well understood as 
symptoms arising from the disease or complications due to medi-
cation or a combination of both. Yet, some inferences are possible. 
For example, episodes of delirium in PD can be linked to anticho-
linergic medication, in which case these can be considered an 
iatrogenic complication. However, in some patients, delirium is a 
symptom mirroring neurotransmitter dysregulation and linked, 
in particular, with serum anticholinergic activity (20). Although 
the cholinergic, dopaminergic as well as inflammatory changes 
[for review, see Ref. (21)], which are thought to underlie delirium 
in PD, are ill-specified, distinguishing an event that might resolve 
quickly once a drug is removed from a recurrent pattern indica-
tive of an underlying disease process is important in informing 
clinical management. This is a particularly salient consideration 
in the case of delirium episodes, the ensuing hysteresis in recovery 
to previous levels of functioning, and the robust association with 
accelerated cognitive decline and mortality in the elderly (22).
Moreover, although PD psychosis, a constellation of hallucina-
tions, delusions, and other symptoms such as sense of presence 
(23), used to be attributed to dopaminergic overstimulation by 
ergot DA agonists in particular (24), its broad phenomenology 
and the lack of a conclusive relationship to levodopa or levodopa-
equivalent dose (LED) in cross-sectional studies [for review, see 
Ref. (25)] suggest a much more complex, if ill-defined, picture. 
While for some patients, abnormal experiences such as visual 
hallucinations may be short-lived if the dose of dopaminergic 
medication can be reduced, for other patients, psychosis may 
herald or coincide with dementia and is the highest predictor of 
nursing home placement (26). Thus, PD psychosis is currently 
understood as emerging from the interaction of an idiosyncratic 
disease process with long-term exposure to dopaminergic medi-
cations: greater age at onset, motor symptom severity dictating 
higher dopaminergic dosing, cognitive impairment, and REM 
sleep behavior disturbance (27) reliably increase the risk for 
PD psychosis (28), indicating that parallel, non-dopaminergic, 
disease-related pathologies are additionally at play. As these 
remain poorly understood, they cannot translate into targeted 
pharmacological intervention. For example, atypical antipsychot-
ics such as clozapine and quetiapine with dual dopaminergic and 
serotonergic action are among the most commonly used in the 
management of psychosis in PD, with comparable efficacy in 
head-to-head trials (29). However, the use of quetiapine is not 
well supported by clinical trials but appears to proceed largely 
on the basis of favorable clinician impressions (30, 31). This 
disparity raises questions that may be addressed in the context 
of large-scale trials employing stratified designs and multivariate 
approaches, equipped to negotiate the heterogeneity of the dis-
ease and nature of these symptoms. Furthermore, the success of 
the selective 5HT2A inverse agonist pimavanserin in reducing 
the positive, but not all the symptoms of psychosis (32), suggests 
that some of its aspects are at minimum amenable to serotonergic 
leverage, although a direct causal role of a serotonergic imbalance 
has yet to be established.
The psychiatric phenomena that may be currently said to 
stand as clear treatment complications are impulse control dis-
orders (ICDs), collectively referring to gambling, hypersexuality, 
punding, as well as dopamine dysregulation syndrome (DDS), 
the compulsive use of antiparkinsonian drugs, which can lead to 
drug induced on-period hypomania (33). DA agonists in particu-
lar (34, 35) have been directly implicated in triggering ICDs in 
vulnerable patients, typically younger, male, and with distinctive 
ventral corticostriatal dopaminergic pathophysiology (36). Given 
that DA agonists can produce ICDs in patients without PD (rest-
less leg syndrome and pituitary adenoma), these behaviors are 
accurately conceptualized as iatrogenic complications.
Psychiatric complications are sometimes also seen after deep 
brain stimulation in a subset of patients and can include ICDs, 
mania, and depression, especially when stimulation targets the 
subthalamic nucleus (37–39). These phenomena are complica-
tions by definition, but their management still represents a chal-
lenge, particularly in the case of complications such as suicidality, 
where the identification of risk factors and intervention in the 
case of preventable ones is a priority (40).
Collectively, these observations support a nosological argu-
ment for distinguishing bona fide neuropsychiatric symptoms of 
PD from complications, predicated on acknowledging the need 
for a better understanding of its heterogeneous process. Certain 
psychiatric symptoms may precede the PD diagnosis itself, rep-
resenting identifiable and clinically relevant disease prodromes 
linked directly to different aspects of neuropathology. The fact 
that severe mood disturbance and RBD represent prospective 
diagnostic criteria for PD constitutes clear evidence that the 
concept of the disease is evolving beyond striatal dopamine 
and motor dysfunction. Other psychiatric manifestations, such 
as episodes of delirium and psychosis, appear as PD progresses 
and may be exacerbated by medication. Their persistence despite 
the removal of potential pharmacological culprits where pos-
sible points to a distinctive underlying disease profile, which 
combined biomarker approaches may eventually isolate, and 
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thus lend support to their classification as symptoms. ICDs are 
better understood to represent a complication of treatment with 
a specific drug class, now used with caution, as are post-operative 
psychiatric complications following DBS. Beyond better science, 
the profound impact of psychiatric symptoms on the quality of 
life of people living with PD, as well as its underdiagnosis, rep-
resents the most compelling observation that multidisciplinary 
approaches that transcend Cartesian dualism and the borders of 
medical specialisms is also a necessity.
AUTHOR COnTRiBUTiOnS
AAK is the sole contributor of this work and has approved it for 
publication.
ACKnOWLEDGMEnTS
AAK thanks D. Joyce and the reviewer for helpful comments 
which greatly improved this piece.
REFEREnCES
1. Weintraub D, Burn DJ. Parkinson’s disease: the quintessential neuropsychiat-
ric disorder. Mov Disord (2011) 26:1022–31. doi:10.1002/mds.23664 
2. Braak H, Braak E, Yilmazer D, Schultz C, De Vos RA, Jansen EN. Nigral and 
extranigral pathology in Parkinson’s disease. J Neural Transm Suppl (1995) 
46:15–31. 
3. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson’s 
disease. Parkinsonism Relat Disord (2010) 16:79–84. doi:10.1016/j.
parkreldis.2009.08.007 
4. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. 
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of 
Parkinson’s disease. Eur J Neurol (2013) 20:16–34. doi:10.1111/ene.12022 
5. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, 
Ahlskog JE, et  al. Anxiety disorders and depressive disorders preceding 
Parkinson’s disease: a case-control study. Mov Disord (2000) 15:669–77. 
doi:10.1002/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5 
6. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. 
Prospective study of phobic anxiety and risk of Parkinson’s disease. Mov 
Disord (2003) 18:646–51. doi:10.1002/mds.10425 
7. Shen CC, Tsai SJ, Perng CL, Kuo BIT, Yang AC. Risk of Parkinson disease 
after depression: a nationwide population-based study. Neurology (2013) 
81:1538–44. doi:10.1212/WNL.0b013e3182a956ad 
8. Quinn NP. Classification of fluctuations in patients with Parkinson’s disease. 
Neurology (1998) 51:S25–9. doi:10.1212/WNL.51.2_Suppl_2.S25 
9. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. 
Mood swings associated with the ‘on-off ’ phenomenon in Parkinson’s disease. 
Psychol Med (1987) 17:899–904. doi:10.1017/S0033291700000702 
10. Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and 
“on-off ” phenomena in Parkinson’s disease. Mov Disord (1990) 5:148–51. 
doi:10.1002/mds.870050210 
11. Richard IH, Frank S, McDermott MP, Wang H, Justus AW, Ladonna KA, et al. 
The ups and downs of Parkinson disease: a prospective study of mood and 
anxiety fluctuations. Cogn Behav Neurol (2004) 17:201–7. 
12. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The 
quality of life in Parkinson’s disease. Mov Disord (2000) 15:216–23. 
doi:10.1002/1531-8257(200003)15:2<216::AID-MDS1003>3.0.CO;2-# 
13. Oehlberg K, Barg FK, Brown GK, Taraborelli D, Stern MB, Weintraub D. 
Attitudes regarding the etiology and treatment of depression in Parkinson’s 
disease: a qualitative study. J Geriatr Psychiatry Neurol (2008) 21:123–32. 
doi:10.1177/0891988708316862 
14. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk 
S, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to 
health care professionals: an international study using the nonmotor symp-
toms questionnaire. Mov Disord (2010) 25:704–9. doi:10.1002/mds.22868 
15. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treat-
ment of depression in Parkinson’s disease. J Geriatr Psychiatry Neurol (2003) 
16:178–83. doi:10.1177/0891988703256053 
16. Garcia-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, Leu-Semenescu S, 
Gallea C, Quattrocchi G, et al. The coeruleus/subcoeruleus complex in rapid 
eye movement sleep behaviour disorders in Parkinson’s disease. Brain (2013) 
136:2120–9. doi:10.1093/brain/awt152 
17. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, 
et  al. Cortical cholinergic function is more severely affected in par-
kinsonian dementia than in Alzheimer disease: an in  vivo positron 
emission tomographic study. Arch Neurol (2003) 60:1745–8. doi:10.1001/
archneur.60.12.1745 
18. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical 
heterogeneity of cognitive impairment and dementia in patients with 
Parkinson’s disease. Lancet Neurol (2010) 9:1200–13. doi:10.1016/
S1474-4422(10)70212-X 
19. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment 
in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. 
Lancet Neurol (2012) 11:697–707. doi:10.1016/S1474-4422(12)70152-7 
20. Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J. The association 
of serum anticholinergic activity with delirium in elderly medical patients. Am 
J Geriatr Psychiatry (1998) 6:31–41. doi:10.1097/00019442-199802000-00005 
21. Vardy ER, Teodorczuk A, Yarnall AJ. Review of delirium in patients 
with Parkinson’s disease. J Neurol (2015) 262:2401–10. doi:10.1007/
s00415-015-7760-1 
22. Witlox J, Eurelings LS, De Jonghe JF, Kalisvaart KJ, Eikelenboom P, Van Gool  
WA. Delirium in elderly patients and the risk of postdischarge mortality, 
institutionalization, and dementia: a meta-analysis. JAMA (2010) 304:443–51. 
doi:10.1001/jama.2010.1013 
23. Fenelon G, Soulas T, Zenasni F, Cleret De Langavant L. The changing face 
of Parkinson’s disease-associated psychosis: a cross-sectional study based on 
the new NINDS-NIMH criteria. Mov Disord (2010) 25:763–6. doi:10.1002/
mds.22839 
24. Stowe RL, Ives NJ, Clarke C, Van Hilten J, Ferreira J, Hawker RJ, et  al. 
Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database 
Syst Rev (2008) (2):CD006564. doi:10.1002/14651858.CD006564.pub2 
25. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson’s disease. J Neurol 
Sci (2010) 289:12–7. doi:10.1016/j.jns.2009.08.014 
26. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home 
placement in Parkinson’s disease: a population-based, prospective study. J Am 
Geriatr Soc (2000) 48:938–42. doi:10.1111/j.1532-5415.2000.tb06891.x 
27. Pacchetti C, Manni R, Zangaglia R, Mancini F, Marchioni E, Tassorelli C, 
et al. Relationship between hallucinations, delusions, and rapid eye movement 
sleep behavior disorder in Parkinson’s disease. Mov Disord (2005) 20:1439–48. 
doi:10.1002/mds.20582 
28. Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, 
et  al. A 12-year population-based study of psychosis in Parkinson disease. 
Arch Neurol (2010) 67:996–1001. doi:10.1001/archneurol.2010.166 
29. Eng ML, Welty TE.  Management of hallucinations and psychosis in 
Parkinson’s disease. Am J Geriatr Pharmacother (2010) 8:316–30. doi:10.1016/j.
amjopharm.2010.08.004 
30. Weintraub D, Katz IR. Pharmacologic interventions for psychosis and agitation 
in neurodegenerative diseases: evidence about efficacy and safety. Psychiatr 
Clin North Am (2005) 28:941–983, ix–x. doi:10.1016/j.psc.2005.09.002 
31. Shotbolt P, Samuel M, David A. Quetiapine in the treatment of psy-
chosis in Parkinson’s disease. Ther Adv Neurol Disord (2010) 3:339–50. 
doi:10.1177/1756285610389656 
32. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. 
Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, 
placebo-controlled phase 3 trial. Lancet (2014) 383:533–40. doi:10.1016/
S0140-6736(13)62106-6 
33. Fox SH, Lang AE. Levodopa-related motor complications – phenomenology. 
Mov Disord (2008) 23(Suppl 3):S509–14. doi:10.1002/mds.22021 
34. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, 
Duda  JE, et  al. Association of dopamine agonist use with impulse control 
4Kehagia Neuropsychiatric Symptoms in Parkinson’s Disease
Frontiers in Psychiatry | www.frontiersin.org June 2016 | Volume 7 | Article 110
disorders in Parkinson disease. Arch Neurol (2006) 63:969–73. doi:10.1001/
archneur.63.7.969 
35. Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C. New onset height-
ened interest or drive for gambling, shopping, eating or sexual activity in 
patients with Parkinson’s disease: the role of dopamine agonist treatment 
and age at motor symptoms onset. J Psychopharmacol (2007) 21:501–6. 
doi:10.1177/0269881106073109 
36. Cilia R, Van Eimeren T. Impulse control disorders in Parkinson’s disease: 
seeking a roadmap toward a better understanding. Brain Struct Funct (2011) 
216:289–99. doi:10.1007/s00429-011-0314-0 
37. Kulisevsky J, Berthier ML, Gironell A, Pascual-Sedano B, Molet J, Pares P. 
Mania following deep brain stimulation for Parkinson’s disease. Neurology 
(2002) 59:1421–4. doi:10.1212/WNL.59.9.1421 
38. Okun MS, Green J, Saben R, Gross R, Foote KD, Vitek JL. Mood changes 
with deep brain stimulation of STN and GPi: results of a pilot study. J Neurol 
Neurosurg Psychiatry (2003) 74:1584–6. doi:10.1136/jnnp.74.11.1584 
39. Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, 
Stefani  A, et  al. Deep brain stimulation for Parkinson disease: an expert 
consensus and review of key issues. Arch Neurol (2011) 68:165. doi:10.1001/
archneurol.2010.260 
40. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M, et  al. 
A multicentre study on suicide outcomes following subthalamic stimula-
tion for Parkinson’s disease. Brain (2008) 131:2720–8. doi:10.1093/brain/ 
awn214 
Conflict of Interest Statement: The author declares that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Kehagia. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
